Study details
Enrolling now
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
NCT IDNCT07401875ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18+
Locations
1 site in TX
What this study is about
This Phase 1 study is testing Nivolumab in people with hc 7366. The primary outcome being measured is Safety and adverse events (AEs).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), ipilimumab (Immune checkpoint inhibitor; blocks CTLA-4 on T cells)
Drug routes
infusion, injection (Injection)
Endpoints
Primary: Safety and adverse events (AEs)
Body systems
Oncology